Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 06 May 2026
The number of family relatives, first-degree or not, who have pancreatic cancer does not appear to affect the risk for intermediate lesions.
Read Full NewsNew York City’s revised Care Coordination Program may help reduce risks for all-cause and HIV-related deaths among people with HIV infection, including those at the highest risk for poor outcomes.
The drug was previously approved for stage 2 T1D.
Findings suggest young females should be assessed and, if at risk, monitored.
Final results from the PaTHway trial show the long-acting parathyroid hormone therapy enabled patients with hypoparathyroidism to achieve independence from high-dose calcium and vitamin D supplements.
Only 12% of patients prescribed testosterone underwent appropriate diagnostic testing, and overprescribing was common in a single-center US study.
The oral modulator of the calcium-sensing receptor targets the causes of ADH1, significantly improving serum and urine calcium levels.
Off-label alternatives for FDA-approved therapies can be as effective, cheaper, and in some cases safer despite never having been submitted for regulatory approval.
1.
FDA Approves Treosulfan as Part of AML/MDS Conditioning Regimen
2.
'Ticking Time Bomb'; Jimmy Carter's Lasting Impact on Cancer; Breast Cancer-CVD Link
3.
Millions of men could benefit from faster scan to diagnose prostate cancer
4.
Experts Debate AQUILA Trial Findings in Smoldering Multiple Myeloma
5.
Key mechanism behind prostate cancer drug resistance reveals potential new treatment strategy
1.
Modern Approaches to Detecting Residual Disease: Clinical Utility and Future Trends
2.
A Closer Look at the Effects of Sickle Cell on Eyesight
3.
Uncovering the Role of Pap Smear in Oncology: A New Frontier in Cancer Detection
4.
Chronic Cancer Survivorship: Managing Long-Term Outcomes with Precision Care
5.
Battling Blood Cancers: Advances in HIV-Related Hematologic Malignancies in the ART Era
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
International Cancer Conference
4.
Asian Symposium on Advancement in Hematology and Oncology
5.
International Lung Cancer Congress®
1.
Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Part IV
2.
Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part V
3.
Benefits of Treatment with CDK4/6 Inhibitors in HR+/HER2- aBC in Clinical Trials and the Real World
4.
First Line Combination Therapy- The Overall Survival Data in NSCLC Patients
5.
Current Scenario of Blood Cancer- Genomic Testing & Advancement in Diagnosis and Treatment
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge